Baird analyst Eric Coldwell lowered the firm’s price target on AdaptHealth to $14 from $17 and keeps an Outperform rating on the shares. The firm said the company consistently underperforms and makes constant missteps but the market is stronger than the company so hope remains that some growth remains.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AHCO:
- AdaptHealth narrows FY23 revenue view to $3.16B-$3.19B from $3.16B-$3.2B
- AdaptHealth reports Q3 EPS ($3.43), consensus 20c
- 3 Best Stocks to Buy Now, 10/23/2023, According to Top Analysts
- AdaptHealth price target lowered to $17 from $21 at Baird
- AdaptHealth price target lowered to $14 from $18 at Truist
